North America Rare Disease Therapeutics Market Set for Significant Growth, with Projected 10.88% CAGR Through 2028 [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The North America Rare Disease Therapeutics Market is experiencing a period of significant growth, with an expected Compound Annual Growth Rate (CAGR) of 10.88% through 2028. This market, which includes a dynamic ensemble of treatments tailored for rare and orphan diseases, has reached a value of USD 40.38 billion as of 2022. The market is benefitting from a combination of factors, including an increase in the prevalence of rare diseases, a supportive regulatory environment, advancements in biotechnology and pharmacology, and a burgeoning patient advocacy movement. Driving Factors Behind Market Growth The market is fueled by several key drivers, chief among them being the increasing prevalence and awareness of rare diseases. The advancements in genetic testing and precision medicine contribute substantially to the diagnosis and treatment of these rare conditions. The supportive regulatory environment in North America, with incentives for drug development under the U.S. Orphan D
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY [Yahoo! Finance]Yahoo! Finance
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCYPR Newswire
- Biologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033 [Yahoo! Finance]Yahoo! Finance
- Microbial Products Market to Gain $286.53 Billion, by 2033 with 6% CAGR: States The Brainy Insights [Yahoo! Finance]Yahoo! Finance
- Why Amgen (AMGN) Outpaced the Stock Market Today [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- AMGN's page on the SEC website